Phizer ($PFE@US) raised its 2022 earnings guidance for 2022 after a strong third quarter. The pharmaceutical company adjusted its earnings per share to $1.78 from the $1.39 expected and revenues to $22.6 billion from the $21 billion expected. The strong sales are attributed to COVID vaccines, the antiviral treatment Paxlovid, and the blood thinner Eliquis. Phizer CEO Albert Bourla said the company is looking beyond COVID and is testing an RSV vaccine for mothers in their second or third trimester of pregnancy.
